In 2017, Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

BACKGROUND. Multinational, randomized, double-blind trial of adjunctive cannabidiol versus placebo in children and young adults 2 to 18 years of age with the Dravet syndrome whose seizures were not controlled by their current antiepileptic-drug regimen. The trial comprised a 4-week baseline period, a 14-week treatment period (2 weeks of dose escalation and 12 weeks of dose maintenance), a 10-day taper period, and a 4-week safety follow-up period.

You can read the full article here => http://www.nejm.org/doi/full/10.1056/NEJMoa1611618?query=featured_home